ScinoPharm Taiwan (台灣神隆), which makes active pharmaceutical ingredients, yesterday said it plans to produce oral formulations as the company’s revenue growth slowed last year from 2012.
The company would talk to local partners to co-develop the new products by using their manufacturing facilities, president and CEO Jo Shen (馬海怡) said.
“There is an excess capacity for oral formulations around the world,” she said of the firm’s hesitance to build its own factory for the products.
The company may seek more than one partner, Shen said, adding that it is developing 70 formulations, but has not decided how many will be manufactured in oral form.
Last year, the company’s revenue grew 11.29 percent last year to NT$5.09 billion (US$166.2 million) from 2012, when revenue increased 15.8 percent to NT$4.57 billion from a year ago, according to the company’s filing to the Taiwan Stock Exchange.
“Formulation-making is to help us maintain the firm’s sales growth in the long term,” Shen said.
Meanwhile, Maxigen Biotech Inc (MBI, 和康生技), which makes cosmetics and medical materials for surgical use, said yesterday that its drug for treating cataracts is expected to enter the Chinese market by the end of this quarter.
The cataract treatment market in China is about 10 million Chinese yuan (US$1.62 million) a year, yet currently just one-sixth of patients receive treatment, company president and chief executive officer Edward Chang (張立言) said.
As the Chinese economy improves, the number of treatments will increase, Chang said.
Chang said the firm aims to increase its gross margin in cosmetics to 30 percent this year from the current 19 percent.
In the long term, sales of the company’s medical materials and cosmetic products will each account for 50 percent of Maxigen’s sales, she said.
Last year, the company posted revenue of NT$232.95 million, up 4.93 percent from NT$222 million a year ago, while operating losses declined to NT$3.56 million last year from NT$10.78 million a year ago, according to the company’s stock exchange filing.
Despite its operating losses, the company posted a net profit of NT$2.58 million last year because of government subsidies, Chang said. In 2012, its net profit was NT$2.67 million.
Shares of ScinoPharm rose 1.11 percent to NT$82.2 yesterday, outperforming the TAIEX, which was up 0.33 percent, while those of Maxigen dropped 0.94 percent to NT$52.5.
‘BIG LOSS’: This year might see the last generation of Huawei’s Kirin chips, as their production would stop next month because they are made using US technology Chinese tech giant Huawei Technologies Co (華為) is running out of processor chips to make smartphones due to US sanctions and would be forced to stop production of its own most advanced chips, a company executive has said, in a sign of growing damage to Huawei’s business from US pressure. Huawei, one of the biggest producers of smartphones and network equipment, is at the center of US-Chinese tension over technology and security. Washington last year cut off Huawei’s access to US components and technology, and those penalties were tightened in May, when the White House barred vendors worldwide from using US
’WHITE BOX’: The open platform would give local firms access to Cisco’s cloud-based mobile network to develop 5G telecom equipment and tap into the global market The Ministry of Economic Affairs (MOEA) yesterday introduced a new 5G “open lab” in collaboration with US-based information technology and networking giant Cisco Systems Inc to address the rapidly growing “white box” 5G networking equipment market. The open lab will be a platform where Taiwanese manufacturers can access Cisco’s cloud-based mobile network to develop their own 5G telecom equipment, such as small-cell base stations, network switches, modems and Internet of things (IoT) devices, a ministry statement said. The open platform would allow Taiwanese manufacturers to tap into the lucrative 5G telecom equipment market, which was previously monopolized by Nokia Oyj, Ericsson AB
CORPORATE SCANDAL: Cathay Life has invested NT$13.3 billion in Bank Mayapada since 2015, but the latest loss of NT$8.8 billion has completely written off its investment Cathay Life Insurance Co (國泰人壽) yesterday said it would recognize an investment loss of NT$8.8 billion (US$298.1 million) in Indonesia’s Bank Mayapada Internasional Tbk PT due to concerns about the lender’s operations amid a corporate scandal. The company said it would revise its earnings result for June, from a net profit of NT$6.52 billion to a net loss of NT$520 million, its first monthly loss over the past 17 months. After booking an investment loss of NT$5.2 billion in Bank Mayapada earlier this year, Cathay Life has so far recognized total investment losses of NT$14 billion in the lender, executive vice president
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported that revenue last month expanded 25 percent annually, but fell 12.8 percent month-on-month to NT$105.96 billion (US$3.59 billion). In the first seven months of this year, the chipmaker’s revenue surged 33.6 percent to NT$727.26 billion, compared with NT$544.46 billion a year earlier. TSMC has said it aims to grow its revenue by more than 20 percent this year. The company has since May 15 stopped taking new orders from Huawei Technologies Co (華為), its second-biggest customer after Apple Inc, due to the US’ restrictions on exports containing US technologies. TSMC has no plans to